Our board are entrepreneurial and inspirational. Leading by example, they take the initiative, encourage innovation, manage risk and embrace new ideas. The board have extensive, varied and proven ion channel expertise and drug discovery knowledge.
Keith McCullagh is an experienced pharmaceutical research & development executive and bioscience entrepreneur...
Lee specialises in steering preclinical CROs to implement robust and effective plans for long-term commercial growth.
Clare is an experienced CIMA qualified Accountant and completed a degree in Mathematics and Statistics...
John has almost 20 years of fundraising, ion channel, drug discovery and drug development experience...
A medicinal chemist by training, John Montana brings over 30 years’ experience in drug discovery and early development...
Steve is an experienced private equity and development capital specialist having enjoyed a successful 30+ year career...
David is a Partner at Maven Capital Partners where he is a member of Maven’s Investment Committee...
Sunil Shah is a Board Observer at Metrion Biosciences and the CEO of the o2h Group...